

Bristol-Myers Squibb Pharmaceuticals

A Division of Bristol-Myers Squibb Australia Pty Ltd A.B.N.33 004 333 322
P.O. Box 39 556 Princes Highway Noble Park Victoria 3174 Australia Tel: (03) 9213 4000 International: +61-3-9213 4000
Fax: International: (+61-3) Managing Director: (03) 9701 1524 Sales & Marketing: (03) 9701 1526 Finance: (03) 9701 1334
Technical Operations: (03) 9795 0968 Export: (03) 9701 1312 Human Resources: (03) 9795 6182
Pharmaceutical Research Institute: (03) 9701 1519 Medical Department: (03) 9701 1508 Regulatory Affairs: (03) 9701 1518

15th February 2007

Dear Pharmacist,

Re: Information relating to Bristol-Myers Squibb Products

- **Diclocil® (dicloxacillin) 1g powder for injection**
- **Florinet® (fludrocortisone acetate) tablets**
- **Iscover® (clopidogrel) tablets**
- **Pronestyl® Injection 1g/10 mL (procainamide hydrochloride)**

I write to inform you of some important information relating to the Bristol-Myers Squibb products listed above.

Iscover® (clopidogrel) - Change in dimensions of outer carton

In recent months, we have been implementing a series of improvements to our manufacturing and packaging processes. One of the improvements has been to make the outer packaging on widely used product lines fully recyclable.

As a result of these changes you will notice that the **outer box** of Iscover® will be larger than currently available packs. The new packs will be introduced to wholesalers in the coming weeks.

Please note that the contents of the carton remain unchanged (tablets and inner calendar foil).

Dimensions of the new outer box are as follows:

New Box:	72 mm x	64 mm x	26 mm
Old Box:	72 mm x	64 mm x	16 mm

It is critical to reassure patients that, despite the change to the outer box, the tablets and the inner calendar foil remain exactly the same.

Following the introduction of the new packs you will also notice a further change to the back of the pack to include a space for a patient label.

If you have any concerns or questions, please contact our **Medical Information Department on 1800 067 567**.

Diclocil® (dicloxacillin) 1g powder for injection – stock shortage

Due to some unforeseen manufacturing issues, BMS Australia (BMSA) is currently experiencing a shortage of stock of Diclocil 1g powder for injection. We have been working with the manufacturing plant to resolve this issue. At this stage we expect to have stock in June 2007. There is a limited emergency supply of Diclocil 500mg powder for injection available. If required please contact your wholesaler to request this emergency stock from BMS.

We apologise for any inconvenience that this may cause for you and your patients. We are pursuing every avenue to expedite the release of new stock as it becomes available.

If you have any questions, please contact our **Customer Services Team on 1800 629 273**.



Bristol-Myers Squibb Pharmaceuticals

Florinef® (fludrocortisone acetate) – improvement to score line

Following feedback that BMSA has received from users of Florinef®, we have made a small but significant change to the tablet which will result in a slightly larger and more clearly defined score line which will improve the ability of patients to break the tablet.

Whilst the usual dose of Florinef in combination with a glucocorticosteroid for the treatment of Addison's disease is 0.1mg daily, doses may range from 0.1mg three times a week to 0.2 mg daily. The improvements to the score line of Florinef will further enhance the flexibility and reliability in dosing for patients who are required to break the tablet. We would like to assure you that the tablet is otherwise equivalent in all other respects.

If you have any questions about these changes, please contact our **Medical Information Department on 1800 067 567**.

Pronestyl Injection 1g/10 mL (procainamide hydrochloride) - deletion

I regret to inform you that due to low and declining rates of use, Bristol-Myers Squibb is discontinuing the supply of Pronestyl Injection 1 g/10mL (procainamide hydrochloride).

The supply of Pronestyl Injection will continue until the end of 2007.

A separate letter containing this information in regard to Pronestyl is being sent to Prescribers simultaneously.

If you have any questions, please contact our **Medical Information Department on 1800 067 567**.

Yours sincerely,



Dr Paul Slade
Medical Director
Ref: DIC/0001/02-07

